Testing the Metal of ERCC2 in predicting the response to platinum-based therapy

John Turchi, Derek S. Woods, Pamela VanderVere-Carozza

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

DNA repair has been shown to affect the cellular response to platinum-based therapy in a variety of cancers; however, translating this knowledge to the clinic has proven diffi cult and yielded mixed results. In this issue of Cancer Discovery , Van Allen and colleagues have analyzed responders and nonresponders to neoadjuvant platinum-based therapy with locally advanced urothelial cancer and identifi ed a series of mutations in the nucleotide excision repair (NER) gene ERCC2 that correlate with the response to platinum-based therapy. This work provides evidence that defects in NER can be exploited to maximize the effi cacy of conventional platinumbased chemotherapy.

Original languageEnglish
Pages (from-to)1118-1119
Number of pages2
JournalCancer Discovery
Volume4
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Platinum
DNA Repair
Metals
Neoplasms
Therapeutics
Drug Therapy
Mutation
Genes

ASJC Scopus subject areas

  • Oncology

Cite this

Testing the Metal of ERCC2 in predicting the response to platinum-based therapy. / Turchi, John; Woods, Derek S.; VanderVere-Carozza, Pamela.

In: Cancer Discovery, Vol. 4, No. 10, 01.10.2014, p. 1118-1119.

Research output: Contribution to journalArticle

Turchi, John ; Woods, Derek S. ; VanderVere-Carozza, Pamela. / Testing the Metal of ERCC2 in predicting the response to platinum-based therapy. In: Cancer Discovery. 2014 ; Vol. 4, No. 10. pp. 1118-1119.
@article{519d74a904c74429b1d4a98f549d8af8,
title = "Testing the Metal of ERCC2 in predicting the response to platinum-based therapy",
abstract = "DNA repair has been shown to affect the cellular response to platinum-based therapy in a variety of cancers; however, translating this knowledge to the clinic has proven diffi cult and yielded mixed results. In this issue of Cancer Discovery , Van Allen and colleagues have analyzed responders and nonresponders to neoadjuvant platinum-based therapy with locally advanced urothelial cancer and identifi ed a series of mutations in the nucleotide excision repair (NER) gene ERCC2 that correlate with the response to platinum-based therapy. This work provides evidence that defects in NER can be exploited to maximize the effi cacy of conventional platinumbased chemotherapy.",
author = "John Turchi and Woods, {Derek S.} and Pamela VanderVere-Carozza",
year = "2014",
month = "10",
day = "1",
doi = "10.1158/2159-8290.CD-14-0893",
language = "English",
volume = "4",
pages = "1118--1119",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Testing the Metal of ERCC2 in predicting the response to platinum-based therapy

AU - Turchi, John

AU - Woods, Derek S.

AU - VanderVere-Carozza, Pamela

PY - 2014/10/1

Y1 - 2014/10/1

N2 - DNA repair has been shown to affect the cellular response to platinum-based therapy in a variety of cancers; however, translating this knowledge to the clinic has proven diffi cult and yielded mixed results. In this issue of Cancer Discovery , Van Allen and colleagues have analyzed responders and nonresponders to neoadjuvant platinum-based therapy with locally advanced urothelial cancer and identifi ed a series of mutations in the nucleotide excision repair (NER) gene ERCC2 that correlate with the response to platinum-based therapy. This work provides evidence that defects in NER can be exploited to maximize the effi cacy of conventional platinumbased chemotherapy.

AB - DNA repair has been shown to affect the cellular response to platinum-based therapy in a variety of cancers; however, translating this knowledge to the clinic has proven diffi cult and yielded mixed results. In this issue of Cancer Discovery , Van Allen and colleagues have analyzed responders and nonresponders to neoadjuvant platinum-based therapy with locally advanced urothelial cancer and identifi ed a series of mutations in the nucleotide excision repair (NER) gene ERCC2 that correlate with the response to platinum-based therapy. This work provides evidence that defects in NER can be exploited to maximize the effi cacy of conventional platinumbased chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84907494624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907494624&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-0893

DO - 10.1158/2159-8290.CD-14-0893

M3 - Article

VL - 4

SP - 1118

EP - 1119

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 10

ER -